Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157
Tel: +81 (0)80-1164-4754
Request a Demo
What our customers are saying
When I think of the future, I think of EvaluatePharma
Global pharmaceutical company
Evaluate Forecasting Excellence
The Value of Outliers in Consensus Forecasting
A perspective on the portfolio strategy of the top 20 pharma companies
Evaluate Forecasting Excellence: The Value of Outliers in Consensus Forecasting analyses the portfolio strategy of the top 20 pharmaceutical companies by leveraging the maximum and minimum forecast within EvaluatePharma® consensus.
Themes of the report include:
- Upside/downside radio metrics that identify companies that could either outperform in the coming years or are at risk.
- Companies that could follow a different trajectory compared to the scenario outlined by consensus forecasts.
- More details on the value of a company’s pipeline for which forecasts are not yet available.
The Value of Outliers in Consensus Forecasting is the first report in the Evaluate Forecasting Excellence series which aims to improve forecasting accuracy to drive more robust decision-making, allocate investment more efficiently and ultimately drive continuous innovation.
Confirm your details on form below to download this report